SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.
Layoffs
Organon Lets Go of 93 Employees in New Jersey in Continuing Workforce Cuts
Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.
April 1, 2025
 · 
2 min read
 · 
Angela Gabriel
FDA signage at its headquarters in Maryland
FDA
FDA Layoffs Continue as Former Commissioner Robert Califf Speaks Out
The latest cuts, which are part of a larger reduction of 10,000 at the Department of Health and Human Services, were reportedly underway Tuesday, with CDER Office of New Drugs Director Peter Stein added to the list of casualties.
April 1, 2025
 · 
2 min read
 · 
Heather McKenzie
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Layoffs
Carisma Lays Off Most of Staff, Eyes Sale of Assets and Company
Cell therapy and oncology–focused Carisma Therapeutics started layoffs late last year. Now the company plans to wind down fully.
April 1, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
Merck continues to build the case for the pulmonary arterial hypertension drug that won FDA approval in 2024.
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
Funding
AIRNA Hits $155M Series B Haul To Advance RNA Editor for Rare Genetic Disease
AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 antitrypsin deficiency.
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Robert F Kennedy Jr speaking at the White House
Government
Calls To End Kennedy’s Leadership Follow Marks’ Abrupt Exit
Analysts at financial firm Cantor Fitzgerald are urging President Donald Trump to rethink his appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services.
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Tenaya Slashes a Third of Workforce To Fund Development of Cardio Gene Therapies
The layoffs will take place throughout 2025 and will mostly affect Tenaya’s research and manufacturing operations. The company is continuing to test its hypertrophic cardiomyopathy gene therapy.
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Climb up, hand help businessman build ladder
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.
March 31, 2025
 · 
4 min read
 · 
Annalee Armstrong
FDA
Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down
The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, who said RFK Jr. does not seek “truth and transparency” but rather “subservient confirmation of his misinformation and lies.”
March 31, 2025
 · 
3 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS